.A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V930/V932 in Patients with Cancers Expressing HER-2 and/or CEA
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2013
At a glance
- Drugs V 932 (Primary) ; V-930 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 20 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 20 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.